Clinical trial
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
NCT00334295 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00334295 |
|---|---|
| Title | Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. |
| Official title | An Open, Non-randomised Multicentre Phase II Study to Assess the Efficacy and Tolerability of a 250 mg Monthly Dose of i.m. Applied Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Carcinoma |
| Intervention type | Drug |
| Interventions | Fulvestrant |
| Enrollment | 35 |
| Start date | Dec 1, 2002 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Jun 7, 2006 |
| Last update posted | Jul 31, 2012 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: